Pradefovir

Summary

Pradefovir (CHEMBL2096895) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 423.8 Da · C17H19ClN5O4P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2096895
Name	Pradefovir
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9604654
Molecular formula	C17H19ClN5O4P
Molecular weight	423.8
InChIKey	GWNHAOBXDGOXRR-HJFSHJIFSA-N

SMILES: C1CO[P@@](=O)(O[C@@H]1C2=CC(=CC=C2)Cl)COCCN3C=NC4=C(N=CN=C43)N

IUPAC name: 9-[2-[[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl]methoxy]ethyl]purin-6-amine

Also known as: Pradefovir, PRADEFOVIR

Parent form; salt/anhydrous children: CHEMBL3989658

Patent coverage: 120 distinct patent families (363 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 348 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).